FDA nod for AZ’s Calquence sets up new Imbruvica showdown

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

AstraZeneca ends another Calquence trial early

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results.

TG Therapeutics cancer trial setback sends shares tumbling

TG Therapeutics (TG) has suffered a setback in its blood cancer drug trial, as the data available was deemed not ready for analysis.

Roche/AbbVie drug could further improve prognosis in CLL

Roche/AbbVie’s cancer drug venetoclax, which is set to become standard of care in chronic lympocytic leukaemia, could further improve prognosis earlier in the disease according to a UK expe

Roche/AbbVie combination could raise standards in CLL

A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing it significantly reduces risk of progression in CLL compared w